A detailed history of Newtyn Management, LLC transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Newtyn Management, LLC holds 2,540,000 shares of TSVT stock, worth $7.98 Million. This represents 2.12% of its overall portfolio holdings.

Number of Shares
2,540,000
Previous 2,485,000 2.21%
Holding current value
$7.98 Million
Previous $9.57 Million 25.31%
% of portfolio
2.12%
Previous 2.09%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.85 - $5.05 $211,750 - $277,750
55,000 Added 2.21%
2,540,000 $12 Million
Q2 2024

Aug 14, 2024

BUY
$3.6 - $5.79 $8.95 Million - $14.4 Million
2,485,000 New
2,485,000 $9.57 Million
Q3 2023

Nov 14, 2023

BUY
$3.14 - $11.2 $7.34 Million - $26.2 Million
2,338,746 Added 317.01%
3,076,490 $12.1 Million
Q2 2023

Aug 14, 2023

SELL
$8.45 - $12.48 $6.48 Million - $9.58 Million
-767,256 Reduced 50.98%
737,744 $7.47 Million
Q1 2023

May 15, 2023

BUY
$9.21 - $14.98 $5.74 Million - $9.33 Million
622,866 Added 70.61%
1,505,000 $15.4 Million
Q4 2022

Feb 14, 2023

SELL
$8.57 - $17.0 $581,611 - $1.15 Million
-67,866 Reduced 7.14%
882,134 $8.27 Million
Q3 2022

Nov 14, 2022

SELL
$12.56 - $17.54 $4.98 Million - $6.96 Million
-396,796 Reduced 29.46%
950,000 $13.8 Million
Q2 2022

Aug 15, 2022

SELL
$10.55 - $18.81 $2.54 Million - $4.53 Million
-241,009 Reduced 15.18%
1,346,796 $17.8 Million
Q1 2022

May 16, 2022

BUY
$11.67 - $26.72 $13.1 Million - $30 Million
1,122,511 Added 241.25%
1,587,805 $27.1 Million
Q4 2021

Feb 14, 2022

BUY
$13.77 - $42.56 $6.41 Million - $19.8 Million
465,294 New
465,294 $11.9 Million

Others Institutions Holding TSVT

About 2seventy bio, Inc.


  • Ticker TSVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,873,600
  • Market Cap $119M
  • Description
  • 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...
More about TSVT
Track This Portfolio

Track Newtyn Management, LLC Portfolio

Follow Newtyn Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Newtyn Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Newtyn Management, LLC with notifications on news.